Drug Landscape ›
STRIBILD ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 26,019
Most-reported reactions
Bone Density Decreased — 4,550 reports (17.49%) Renal Injury — 3,304 reports (12.7%) Skeletal Injury — 3,020 reports (11.61%) Chronic Kidney Disease — 2,482 reports (9.54%) Tooth Loss — 2,455 reports (9.44%) Bone Loss — 2,134 reports (8.2%) Osteonecrosis — 2,095 reports (8.05%) Renal Failure — 2,052 reports (7.89%) Tooth Injury — 1,970 reports (7.57%) Multiple Fractures — 1,957 reports (7.52%)
Source database →
STRIBILD in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is STRIBILD approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for STRIBILD in United States?
Vancouver Infectious Diseases Centre is the originator. The local marketing authorisation holder may differ — check the official source linked above.